Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Vilazodone

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,993Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Wall Street's not modeling threats to Allergan's older meds
    Wall Street's not modeling threats to Allergan's older meds

    18 Nov 2016

    // Carly Helfand FIERCE PHARMA

    http://www.fiercepharma.com/pharma/wall-street-s-not-modeling-threats-to-allergan-s-older-meds-and-it-s-hurting-shares-analyst

    Carly Helfand FIERCE PHARMA
    18 Nov 2016
    Share Share
    Actavis' Viibryd (Vilazodone HCL 20Mg) Receives Supplemental Approval in USA For MDD
    Actavis' Viibryd (Vilazodone HCL 20Mg) Receives Supplemental Approval in USA For MDD

    17 Mar 2015

    // Press Release ACTAVIS

    http://www.actavis.com/NEWS/News/Thomson-Reuters/Actavis-Receives-FDA-Approval-for-VIIBRYD-vilazod

    Press Release ACTAVIS
    17 Mar 2015
    Share Share